ProCE Banner Activity

CME

Next-Generation Endocrine Therapies: Opportunities in ER+/HER2- Breast Cancer Care

Video

Expert faculty discuss next-generation endocrine therapies used in ER+/HER2- breast cancer and how results from relevant clinical trials can change the landscape of breast cancer treatment.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: December 18, 2023

Expiration: December 17, 2024

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Professor of Medicine
Director, Glenn Family Breast Center
Winship Cancer Institute
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This program is intended for physicians, pathologists, and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise current and emerging data and guidelines to inform the use of biomarkers and genomic classifiers to assess the risk of recurrence and the role of common mutations (ESR1) in predicting response to SERDs

  • Develop treatment strategies for patients with ER+/HER2- breast cancer, taking into consideration the rationale, mechanisms of action, and latest efficacy and safety data of
    novel oral SERDs and other ER-targeting therapies

  • Individualize the selection and sequence of systemic therapy for patients with ER-positive breast cancer, considering clinical presentation, prior treatment course, and patient comorbidities and goals

  • Formulate supportive care strategies to manage adverse events and promote oral therapy compliance using available safety and toxicity data for oral SERDs and other ER-targeting therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Erika P. Hamilton, MD: researcher (paid to institution): Abbvie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics,Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics , Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks; consultant/advisor (paid to institution): AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Gilead Sciences, Greenwich LifeSciences, Janssen, Jazz Pharmaceuticals, Lilly, Loxo, Medical Pharma Services, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Stemline Therapeutics, Theratechnologies, Tubulis, Verascity Scine, Zentalis Pharmaceuticals.

Kevin Kalinsky, MD, MS

Professor of Medicine
Director, Glenn Family Breast Center
Winship Cancer Institute
Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Merck, Mersana, Myovant Sciences, Puma Biotechnology, Seattle Genetics, Silicon Biosystems, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 18, 2023, through December 17, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.